Print Page | Sign In | Join
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 9 of 27
 |<   <<   <  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  >   >>   >| 

Scientific Advancements
Thursday, February 2, 2023   (0 Comments - view/add)
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fi »
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis Patient d...
Tuesday, January 31, 2023   (0 Comments - view/add)
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formula »
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancr...
Tuesday, January 31, 2023   (0 Comments - view/add)
INSIGHTEC ANNOUNCES POSITIVE COVERAGE DECISION BY CIGNA FOR FOCUSED ULTRASOUN »
INSIGHTEC ANNOUNCES POSITIVE COVERAGE DECISION BY CIGNA FOR FOCUSED ULTRASOUND TO TREAT ESSENTIAL TREMOR Cigna is the...
Tuesday, January 31, 2023   (0 Comments - view/add)
Arima Genomics Announces Agreement with Protean BioDiagnostics to Make Arima Gene Fusion Test Widely »
Arima Genomics Announces Agreement with Protean BioDiagnostics to Make Arima Gene Fusion Test Widely Available to Clinicia...
Wednesday, January 25, 2023   (0 Comments - view/add)
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII »
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII January 25, 2023 08:...
Monday, January 23, 2023   (0 Comments - view/add)
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Preventio »
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboe...
Monday, January 23, 2023   (0 Comments - view/add)
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasm »
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center...
Thursday, January 19, 2023   (0 Comments - view/add)
Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-00 »
Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004 January 18, 202...
Thursday, January 19, 2023   (0 Comments - view/add)
VySpine Announces FDA Clearance for LumiVy Lumbar IBF with NanoVy Ti »
VySpine Announces FDA Clearance for LumiVy Lumbar IBF with NanoVy Ti January 17, 2023 11:58 AM Eastern Standard Time...
Wednesday, January 18, 2023   (0 Comments - view/add)
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy »
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy   KemPharm...
Tuesday, January 17, 2023   (0 Comments - view/add)
Akron Bio Receives Eligibility Confirmation from PMDA in Japan for the Commercialization of Virus In »
Akron Bio Receives Eligibility Confirmation from PMDA in Japan for the Commercialization of Virus Inactivated Human Fibron...
Friday, January 13, 2023   (0 Comments - view/add)
University of South Florida Health, Northwell Health, Tampa General Hospital and Formlabs earn natio »
University of South Florida Health, Northwell Health, Tampa General Hospital and Formlabs earn national recognition for 3D...
Tuesday, January 10, 2023   (0 Comments - view/add)
Arthrex Receives FDA Clearance for TightRope® Implant as First, Only Device Cleared for Pediatric AC »
Arthrex Receives FDA Clearance for TightRope® Implant as First, Only Device Cleared for Pediatric ACL Surgery Surgical...
Monday, January 9, 2023   (0 Comments - view/add)
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treat »
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol ®  Cyclo™ for the Treatment of Earl...
Monday, January 9, 2023   (0 Comments - view/add)
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIO »
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA WESTON, Fla...
Thursday, January 5, 2023   (0 Comments - view/add)
Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-re »
Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allo...
Wednesday, January 4, 2023   (0 Comments - view/add)
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited »
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (S...
Tuesday, January 3, 2023   (0 Comments - view/add)
Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd. »
Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd. STUART, Fla. ,  Jan. 3, 2023 &nbs...
Tuesday, January 3, 2023   (0 Comments - view/add)
Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CS »
Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment...
Tuesday, January 3, 2023   (0 Comments - view/add)
Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CS »
Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Trea...
Thursday, December 29, 2022   (0 Comments - view/add)
H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC »
H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC December 29, 2022 07:00 E...
Wednesday, December 28, 2022   (0 Comments - view/add)
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at »
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Mia...
Wednesday, December 21, 2022   (0 Comments - view/add)
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Id »
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (...
Thursday, December 15, 2022   (0 Comments - view/add)
Tuesday, December 13, 2022   (0 Comments - view/add)
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM® »
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®  ...
Thursday, December 8, 2022   (0 Comments - view/add)
HCW Biologics Enters CRADA with National Cancer Institute »
HCW Biologics Enters CRADA with National Cancer Institute NCI Activated as Clinical Site for Phase 1b/2 Clinical Tri...
Thursday, December 8, 2022   (0 Comments - view/add)
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Amp »
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod...
Monday, December 5, 2022   (0 Comments - view/add)
First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule »
First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation...
Wednesday, November 30, 2022   (0 Comments - view/add)
Philips Signs Research Agreement to Explore New Magnet Technologies »
Philips Signs Research Agreement to Explore New Magnet Technologies Collabo...
Wednesday, November 30, 2022   (0 Comments - view/add)
First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery F »
First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipa...
Tuesday, November 22, 2022   (0 Comments - view/add)
U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the fir »
U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for he...
Tuesday, November 22, 2022   (0 Comments - view/add)
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for t »
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pan...
Friday, November 18, 2022   (0 Comments - view/add)
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of I »
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia...
Thursday, November 17, 2022   (0 Comments - view/add)
Medtronic begins US launch of 7-day insulin infusion set »
Medtronic begins US launch of 7-day insulin infusion set By Andrea Park Nov 17, 2022 12:41pm The thin plastic tubing...
Monday, November 14, 2022   (0 Comments - view/add)
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Eval »
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® a...

Displaying page 9 of 27
 |<   <<   <  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  >   >>   >| 

About BioFlorida

BioFlorida is the voice of Florida's life sciences industry, representing 8,600 establishments and research organizations in the BioPharma, MedTech, Digital Health and Health Systems that collectively employ nearly 107,000 Floridians. Source: TEConomy/BIO (released 2022)